





CLAIM AMENDMENTS





1. (currently amended): An expanded porphyrin or a conjugate thereof comprising at least five pyrrole rings or pyrrole mimics wherein at least two NH or N moieties contained in said pyrrole rings or pyrrole mimics are replaced by S, Se and/or Te; said replacements occurring in non-adjacent pyrrole rings or pyrrole mimics;


wherein said expanded porphyrin is substituted with at least one R<sup>1</sup> moiety which is cationic under physiological conditions; and

wherein said porphyrin may optionally be substituted by one or more non-interfering substituents and one or more carbons contained in a pyrrole ring may be replaced by O or S.

2. (currently amended): The expanded porphyrin or conjugate of claim 1, wherein the expanded porphyrin is of the formula








wherein each X is independently S, Se or Te; and

wherein at least one R<sup>1</sup> comprises a substituent that is in cationic form at physiological pH; the remaining R<sup>1</sup> represent H, alkyl (1-6C), alkenyl (2-6C) or aryl, each alkyl, alkenyl and/or aryl optionally containing a substituent that is in cationic form at physiological pH; and

wherein each of said formulas (1-20) may optionally contain one or more non-interfering substituents, and

wherein one or more C contained in a pyrrole ring may be replaced by O or S.

3. (original): The expanded porphyrin or conjugate of claim 2, wherein at least one  $R^1$  is



4. (original): The expanded porphyrin or conjugate of claim 1 wherein the expanded porphyrin is Se2SAP.

5. (original): A pharmaceutical composition for treating tumors which comprises as active ingredient the expanded porphyrin or conjugate of claim 1 in admixture with a physiologically acceptable excipient.

6. (withdrawn): A method to treat tumors in a subject, which method comprises administering to a subject in need of such treatment an effective amount of the expanded porphyrin or conjugate of claim 1 or a pharmaceutical composition thereof.

7-8. (canceled)